99mTc-CNDG SPECT/CT in Brain Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: 99mTc-CNDG SPECT/CT.
- Who it may be relevant to
- Registry conditions: Intracranial Tumor. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Application of 99mTc-CNDG SPECT/CT Imaging in the Diagnosis of Brain Tumors
Overview
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are: 1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type? Participants will: Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Interventions
- Diagnostic test 99mTc-CNDG SPECT/CT
FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
Primary outcome measures
- SUVmax [Time frame: 1month]
Eligibility criteria
Inclusion criteria
- Patients with clinical diagnosis of brain tumor;
- Be at least 18 years old;
- The final pathological results could be obtained by surgery or biopsy;
- Informed consent and the ability to be followed up;
- Those who did not meet the exclusion criteria.
Exclusion criteria
- Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
- Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
- Severe hypersensitivity or hypersensitivity to radiocontrast agents;
- Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
- Patients receiving radiotherapy and chemotherapy;
- Being pregnant or breastfeeding.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Peking Union Medical College Hospital — Beijing
Identifiers
NCT: NCT06362304 · 2024-DG-01